Clinical Trial

A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors

Name: A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors — clinical trial record (NCT07719920)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HW221043 tablets in participants with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).

Trial Details

NCT Number	NCT07719920
Lead Sponsor	Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Conditions	Advanced Solid Tumors
Enrollment	99 participants
Start Date	2026-07-30
Primary Completion	2029-06-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-22